{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:49:55Z","timestamp":1770839395509,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,12,23]],"date-time":"2017-12-23T00:00:00Z","timestamp":1513987200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,12,23]],"date-time":"2017-12-23T00:00:00Z","timestamp":1513987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1111\/jcpt.12660","type":"journal-article","created":{"date-parts":[[2017,12,24]],"date-time":"2017-12-24T11:04:04Z","timestamp":1514113444000},"page":"408-413","source":"Crossref","is-referenced-by-count":24,"title":["Association of CYP2C9*3 with phenytoin-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis"],"prefix":"10.1155","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3349-6244","authenticated-orcid":false,"given":"X.","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Dermatology; The Affiliated Hospital of Southwest Medical University; Luzhou City China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology; The Affiliated Hospital of Southwest Medical University; Luzhou City China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Allergy; Chongqing General Hospital; Chongqing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,12,23]]},"reference":[{"key":"10.1111\/jcpt.12660-BIB0001|jcpt12660-cit-0001","unstructured":"Phenytoin. MedlinePlus https:\/\/medlineplus.gov\/druginfo\/meds\/a682022.html"},{"key":"10.1111\/jcpt.12660-BIB0002|jcpt12660-cit-0002","first-page":"625","article-title":"Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy","volume":"13","author":"Paulmann","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1111\/jcpt.12660-BIB0003|jcpt12660-cit-0003","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12660-BIB0004|jcpt12660-cit-0004","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tox.2004.12.022","article-title":"Clinical heterogeneity of drug hypersensitivity","volume":"209","author":"Roujeau","year":"2005","journal-title":"Toxicology"},{"key":"10.1111\/jcpt.12660-BIB0005|jcpt12660-cit-0005","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.yebeh.2010.08.007","article-title":"Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China","volume":"19","author":"Wu","year":"2010","journal-title":"Epilepsy Behav"},{"key":"10.1111\/jcpt.12660-BIB0006|jcpt12660-cit-0006","unstructured":"US Food and Drug Administration Clinical Review, Adverse Events: Carbamazepine https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/016608s098,020712s029,021710_clinrev.pdf"},{"key":"10.1111\/jcpt.12660-BIB0007|jcpt12660-cit-0007","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","article-title":"Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese","volume":"48","author":"Man","year":"2007","journal-title":"Epilepsia"},{"key":"10.1111\/jcpt.12660-BIB0008|jcpt12660-cit-0008","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/j.1528-1167.2008.01719.x","article-title":"Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population","volume":"49","author":"Locharernkul","year":"2008","journal-title":"Epilepsia"},{"key":"10.1111\/jcpt.12660-BIB0009|jcpt12660-cit-0009","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/tpj.2016.10","article-title":"Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population","volume":"17","author":"Chang","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"10.1111\/jcpt.12660-BIB0010|jcpt12660-cit-0010","unstructured":"US Food and Drug Administration Information for healthcare professionals: dangerous or even fatal skin reactions-carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics) https:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124788.htm"},{"key":"10.1111\/jcpt.12660-BIB0011|jcpt12660-cit-0011","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1055\/s-0034-1375684","article-title":"HLA-B*1502 increases the risk of phenytoin or lamotrigine induced Stevens-Johnson Syndrome\/toxic epidermal necrolysis: evidence from a meta-analysis of nine case-control studies","volume":"65","author":"Li","year":"2014","journal-title":"Drug Res"},{"key":"10.1111\/jcpt.12660-BIB0012|jcpt12660-cit-0012","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1517\/17425255.2015.1053463","article-title":"CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects","volume":"11","author":"Franco","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1111\/jcpt.12660-BIB0013|jcpt12660-cit-0013","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/clpt.2014.159","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C9 and HLA-B genotype and phenytoin dosing","volume":"96","author":"Callaghan","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12660-BIB0014|jcpt12660-cit-0014","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00228-004-0753-0","article-title":"Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions","volume":"60","author":"Lee","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jcpt.12660-BIB0015|jcpt12660-cit-0015","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12660-BIB0016|jcpt12660-cit-0016","first-page":"727","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis","volume":"18","author":"Wells","year":"2014","journal-title":"Appl Eng Agric"},{"key":"10.1111\/jcpt.12660-BIB0017|jcpt12660-cit-0017","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1111\/jcpt.12660-BIB0018|jcpt12660-cit-0018","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jnci\/81.2.107","article-title":"Publication bias and dissemination of clinical research","volume":"81","author":"Begg","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/jcpt.12660-BIB0019|jcpt12660-cit-0019","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jama.2014.7859","article-title":"Genetic variants associated with phenytoin-related severe cutaneous adverse reactions","volume":"312","author":"Chung","year":"2014","journal-title":"JAMA"},{"key":"10.1111\/jcpt.12660-BIB0020|jcpt12660-cit-0020","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/jhg.2015.47","article-title":"Association analysis of CYP2C9*3 and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children","volume":"60","author":"Suvichapanich","year":"2015","journal-title":"J Hum Genet"},{"key":"10.1111\/jcpt.12660-BIB0021|jcpt12660-cit-0021","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/FPC.0000000000000211","article-title":"Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population","volume":"26","author":"Tassaneeyakul","year":"2016","journal-title":"Pharmacogenet Genomics"},{"key":"10.1111\/jcpt.12660-BIB0022|jcpt12660-cit-0022","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00228-017-2250-2","article-title":"Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions","volume":"73","author":"Yampayon","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jcpt.12660-BIB0023|jcpt12660-cit-0023","first-page":"2709","article-title":"Update on the genetic polymorphisms of drug-metabolizing enzymes in antiepileptic drug therapy","volume":"3","author":"Saruwatari","year":"2010","journal-title":"Pharmaceutical"},{"key":"10.1111\/jcpt.12660-BIB0024|jcpt12660-cit-0024","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2133\/dmpk.DMPK-10-RG-059","article-title":"Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thai patients taking warfarin","volume":"25","author":"Sangviroon","year":"2010","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1111\/jcpt.12660-BIB0025|jcpt12660-cit-0025","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/FPC.0b013e32834282b8","article-title":"Positive and negative associations of HLA class I alleles with allopurinol induced SCARs in Koreans","volume":"21","author":"Kang","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1111\/jcpt.12660-BIB0026|jcpt12660-cit-0026","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12660-BIB0027|jcpt12660-cit-0027","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1212\/01.wnl.0000334295.50403.4c","article-title":"Cross-sensitivity of skin rashes with antiepileptic drug use","volume":"71","author":"Hirsch","year":"2008","journal-title":"Neurology"},{"key":"10.1111\/jcpt.12660-BIB0028|jcpt12660-cit-0028","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamadermatol.2013.4114","article-title":"Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"149","author":"Tangamornsuksan","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1111\/jcpt.12660-BIB0029|jcpt12660-cit-0029","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0022-3565(25)32544-9","article-title":"Anticonvulsant toxicity in vitro: possible role of arene oxides","volume":"217","author":"Spielberg","year":"1981","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/jcpt.12660-BIB0030|jcpt12660-cit-0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12887-016-0603-0","article-title":"Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy","volume":"16","author":"Chaudhary","year":"2016","journal-title":"BMC Pediatr"},{"key":"10.1111\/jcpt.12660-BIB0031|jcpt12660-cit-0031","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/cea.12184","article-title":"Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response","volume":"43","author":"Yun","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1111\/jcpt.12660-BIB0032|jcpt12660-cit-0032","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.4049\/jimmunol.1302306","article-title":"Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01","volume":"192","author":"Yun","year":"2014","journal-title":"J Immunol"},{"key":"10.1111\/jcpt.12660-BIB0033|jcpt12660-cit-0033","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1136\/annrheumdis-2014-205577","article-title":"Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin","volume":"74","author":"Chung","year":"2015","journal-title":"Ann Rheum Dis"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12660","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12660\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T05:11:59Z","timestamp":1751173919000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,23]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12660","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12,23]]}}}